anayamalik, Author at European Medical Journal - Page 100 of 120

Functional Outcomes After Respiratory Failure Explored

Respiratory failure impacts millions annually in the U.S., leaving many survivors with lasting physical, cognitive, and quality-of-life impairments.

Omega-3 Diet Reduces Prostate Cancer Progression

A recent Phase II clinical trial has revealed promising results for men with low-grade prostate cancer on active surveillance (AS).

VISIBLE Study Drives Diversity in Psoriasis Research

In an effort to improve psoriasis research, the VISIBLE clinical trial has made significant strides in diversity, enrolling participants with skin of color (SoC) at an accelerated rate.

Dynamic Model Improves Migrant Tuberculosis Detection

Tuberculosis (TB) remains a persistent health concern among migrants to low-TB-incidence countries, including Canada.

Estrogen-Progesterone Therapy Linked to Autoimmune Risks

A recent study exploring the impact of estrogen and progesterone analog supplementation on autoimmune conditions reveals a concerning association with several diseases.

Predictors of Psoriatic Arthritis in Juvenile Arthritis

Insights into predicting psoriatic arthritis (PsA) in juvenile idiopathic arthritis (JIA) patients, 18 years after their initial diagnosis, were shared in a recent study.

Burn Patients Face Pneumonia Risk Surge

A newly published study highlights a critical connection between inhalation injury severity and the risk of developing nosocomial pneumonia (NP) in burn patients.

Can Exercise and Brain Stimulation Help Patients With ALS?

A recent meta-analysis sheds light on nonpharmacologic treatments for amyotrophic lateral sclerosis (ALS), specifically active exercise and noninvasive brain stimulation (NIBS).

Lessons from HIV/AIDS and COVID-19

The global challenges posed by HIV/AIDS and COVID-19 provide critical insights for managing future infectious disease outbreaks, according to a recent study by Anthony S Fauci and Gregory K Folkers.

Thin Melanomas: A Critical 0.8 mm Threshold

A recent cohort study involving 144,447 participants has found a crucial threshold in melanoma risk for tumors with a Breslow thickness between 0.8 and 1.0 mm.